One of the major challenges this market faces is the lack of effective treatment options for late-stage kidney cancer. While some drugs have increased survival rates for early-stage patients, relapse and drug resistance continues to be a problem. The overall approvals of new drugs are also low due to high failure rates in clinical trials. Another challenge is the presence of various sub-types of kidney cancer, each with its own genetic patterns and response to treatment. Developing drugs that can target multiple sub-types effectively is difficult. Further, the costs of R&D for precision medicines and immunotherapies are very high, acting as a deterrent for smaller companies.
Market Opportunities: Increasing funding for kidney cancer
Government initiatives and increasing funding for kidney cancer research presents a major opportunity for growth in the kidney cancer drugs market. Kidney cancer is a serious health issue affecting many lives every year. However, with more support and resources dedicated to advancing treatment methods, there is hope that outcomes can improve significantly over the coming years. For instance, in September 2022, Weill Cornell Medicine secured a three-year grant worth USD 1 million from the Department of Defense's Kidney Cancer Research Program. The funding aims to support investigations into the function of the protein ATF4 in clear cell renal cell carcinoma (ccRCC), a type of kidney cancer.
Kidney Cancer Drugs Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients